HNSCC

This early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…

This study tests whether adding two immunotherapy drugs (cemiplimab and cetuximab) to standard chemotherapy before surgery is safe and effective for people with advanced head and neck cancer. The goal is to see if this combination can help patients avoid needing radiation therapy…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried other treat…

This study tests a new drug (HCB101) combined with an existing immunotherapy (pembrolizumab) for people with advanced head and neck cancer that no longer responds to platinum chemotherapy. About 50 adults will receive weekly infusions of HCB101 plus pembrolizumab every three week…

This early-phase study tests a new drug called ALX2004 in people with advanced lung, head and neck, colorectal, or esophageal cancers that have stopped responding to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer …

This early study tests a new treatment for advanced head and neck cancer that has come back or spread. It uses a patient's own immune cells (called TILs) grown in a lab and given back along with a drug that helps the immune system attack the tumor. The main goal is to check safet…

This study tests a new drug called DCSZ11 combined with standard treatments in people with advanced or metastatic solid tumors. The goal is to see if the combination is safe and can shrink tumors or keep them from growing. About 9 adults with certain cancers, including head and n…

This early-stage study tests an experimental injection called TI-0093 in 12 people with HPV-16 positive cancers (like head and neck or cervical cancer) that have returned or spread. The main goals are to check safety, find the best dose, and see how the body responds. It is not a…

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. Participants receive the drug and are monitored for side effects a…

This early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with recurrent or metastatic head and neck squamous cell carcinoma that worsened after standard treatment. The main goals are to see if the combination is safe and whether it can shrink tu…

This early-phase study tests a new drug, VLPONC-01, injected directly into head and neck tumors to see if it's safe and can shrink tumors. About 41 adults with advanced head and neck cancer will receive the injection alone or with an immunotherapy drug (pembrolizumab). The goal i…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This early-phase trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also compare different doses in people with head and …

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This early-stage study tests a special dye (IRDye800) attached to the cancer drug panitumumab. The dye makes cancer cells glow under a special camera during surgery, helping doctors see exactly where the cancer is. About 18 adults with head and neck cancer will receive the dye be…

This study is testing a new device that takes detailed PET-CT pictures of a tumor right after it is removed during surgery. The goal is to help surgeons see if any cancer cells are left behind, so they can remove more tissue if needed. About 50 adults with solid tumors will take …

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already receiving immunotherapy. Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in immune cells in the blood ca…